中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2014年
15期
16-17
,共2页
参麦注射液%肝硬化%失代偿期%凝血功能%凝血酶原时间%纤维蛋白原
參麥註射液%肝硬化%失代償期%凝血功能%凝血酶原時間%纖維蛋白原
삼맥주사액%간경화%실대상기%응혈공능%응혈매원시간%섬유단백원
Shenmai injection%Liver cirrhosis%Decompensated period%Coagulation function
目的：观察参麦注射液用于改善肝硬化失代偿期患者凝血功能的效果。方法：将78例失代偿期肝硬化患者随机分为观察组和对照组各39例。对照组采用综合治疗，包括卧床、营养支持、维持水电解质酸碱平衡、护肝、降酶、退黄、抗病毒等治疗；观察组在此基础上给予20 ml参麦注射液加入5％葡萄糖注射液250 ml静脉滴注，1次/d，2组均治疗30天为1个疗程。分别于治疗前和疗程结束时测定患者凝血酶原时间（ PT）、活化部分凝血酶原时间（ APTT）和纤维蛋白原（ FIB）等凝血功能指标。结果：治疗前对照组PT、APTT和FIB分别为17．6±3．1秒、51．8±4．7秒、1．8±1．2g/L；治疗后对照组PT、APTT和FIB分别为16．1±3．3秒、47．2±5．1秒、1．9±1．4g/L；治疗前观察组PT、APTT和FIB分别为17．8±3．2秒5、2．1±4．9秒、1．7±1．1g/L；治疗后观察组PT、APTT和FIB分别为14．6±3．0秒、42．5±4．8秒、2．2±1．5g/L。治疗前2组患者PT、APTT和FIB指标均无统计学差异（P＞0．05）。同组患者治疗后上述指标均较治疗前改善，观察组改善程度比对照组更为显著（均P＜0．05）。结论：参麦注射液对于改善肝硬化失代偿期患者的凝血功能具有显著的临床效果。
目的：觀察參麥註射液用于改善肝硬化失代償期患者凝血功能的效果。方法：將78例失代償期肝硬化患者隨機分為觀察組和對照組各39例。對照組採用綜閤治療，包括臥床、營養支持、維持水電解質痠堿平衡、護肝、降酶、退黃、抗病毒等治療；觀察組在此基礎上給予20 ml參麥註射液加入5％葡萄糖註射液250 ml靜脈滴註，1次/d，2組均治療30天為1箇療程。分彆于治療前和療程結束時測定患者凝血酶原時間（ PT）、活化部分凝血酶原時間（ APTT）和纖維蛋白原（ FIB）等凝血功能指標。結果：治療前對照組PT、APTT和FIB分彆為17．6±3．1秒、51．8±4．7秒、1．8±1．2g/L；治療後對照組PT、APTT和FIB分彆為16．1±3．3秒、47．2±5．1秒、1．9±1．4g/L；治療前觀察組PT、APTT和FIB分彆為17．8±3．2秒5、2．1±4．9秒、1．7±1．1g/L；治療後觀察組PT、APTT和FIB分彆為14．6±3．0秒、42．5±4．8秒、2．2±1．5g/L。治療前2組患者PT、APTT和FIB指標均無統計學差異（P＞0．05）。同組患者治療後上述指標均較治療前改善，觀察組改善程度比對照組更為顯著（均P＜0．05）。結論：參麥註射液對于改善肝硬化失代償期患者的凝血功能具有顯著的臨床效果。
목적：관찰삼맥주사액용우개선간경화실대상기환자응혈공능적효과。방법：장78례실대상기간경화환자수궤분위관찰조화대조조각39례。대조조채용종합치료，포괄와상、영양지지、유지수전해질산감평형、호간、강매、퇴황、항병독등치료；관찰조재차기출상급여20 ml삼맥주사액가입5％포도당주사액250 ml정맥적주，1차/d，2조균치료30천위1개료정。분별우치료전화료정결속시측정환자응혈매원시간（ PT）、활화부분응혈매원시간（ APTT）화섬유단백원（ FIB）등응혈공능지표。결과：치료전대조조PT、APTT화FIB분별위17．6±3．1초、51．8±4．7초、1．8±1．2g/L；치료후대조조PT、APTT화FIB분별위16．1±3．3초、47．2±5．1초、1．9±1．4g/L；치료전관찰조PT、APTT화FIB분별위17．8±3．2초5、2．1±4．9초、1．7±1．1g/L；치료후관찰조PT、APTT화FIB분별위14．6±3．0초、42．5±4．8초、2．2±1．5g/L。치료전2조환자PT、APTT화FIB지표균무통계학차이（P＞0．05）。동조환자치료후상술지표균교치료전개선，관찰조개선정도비대조조경위현저（균P＜0．05）。결론：삼맥주사액대우개선간경화실대상기환자적응혈공능구유현저적림상효과。
Objective:To observe the effects of improvement of coagulation function in patients with decompensated liver cirrhosis trea -ted by Shenmai injection .Methods:78 patients with decompensated liver cirrhosis were divided into observation group and control group with 39 patients each group .Control group were treated by comprehensive therapy such as stay in bed , nutrition support , keeping water , electrolyte and acid base balance , hepatic protection , decline the enzyme , removing jaundice , antiviral.Based on these , observation group were treated by Shenmai injection(20 ml Shenmai injection added into 250 ml 5%glucose injection ), once a day.Two groups were treated for 30 days for a course of treatment.The PT , APTT, FIB were detected before and after treatment .Results:The PT, APTT, FIB in control group were (17.6 ±3.1)s、(51.8 ±4.7)s、(1.8 ±1.2)g/L respectively before treatment .After treatment, the PT , APTT, FIB in control group were(16.1 ±3.3)s、(47.2 ±5.1)s、( 1.9 ±1.4)g/L respectively.The PT, APTT, FIB in observation group were (17.8 ±3.2)s、(52.1 ±4.9)s、 (1.7 ±1.1)g/L respectively .After treatment, the PT, APTT, FIB in observation group were (14.6 ± 3.0)s、( 42.5 ±4.8)s、(2.2 ±1.5)g/L respectively.The differences of PT, APTT and FIB between two groups before treatment were no statistically significant(P>0.05).After treatment, the PT, APTT and FIB were improved, the improvement in observation group was bet-ter than control group (P<0.05).Conclusion:Shenmai injection has significant clinical effect on the improvement of coagulation function in patients with ddecompensated liver cirrhosis .
